Search results
Showing 106 to 120 of 277 results for diarrhoea
This guideline covers helping adults and young people over 16 who are dependent on opioids to stop using drugs. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.
Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471)
We have withdrawn this guidance. Allergan has stopped marketing eluxadoline (Truberzi) for commercial reasons and its marketing authorisation has been withdrawn.
Percutaneous thoracic duct embolisation for persistent chyle leak (IPG755)
Evidence-based recommendations on percutaneous thoracic duct embolisation for persistent chyle leak. In this procedure, under general anaesthesia, ultrasound and X-rays are used to create an image of the thoracic duct and find the leak. Then, using a needle, a tube is inserted through the abdominal wall (percutaneous) and guided into the thoracic duct. Small metal coils and medical glue are inserted through the tube and used to plug the leak (embolisation). The aim is to stop the leak.
View recommendations for IPG755Show all sections
Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)
Summary of the evidence on delafloxacin for community-acquired pneumonia in adults
High dose rate brachytherapy for carcinoma of the cervix (IPG160)
Evidence-based recommendations on high dose rate brachytherapy for carinoma of the cervix. This involves giving radiation at a high dose rate to the cervix (reducing the timeframe compared with low or medium dose rates) to treat the cancer.
View recommendations for IPG160Show all sections
Sections for IPG160
Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making
This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care.
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.
Evidence-based recommendations on selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver. This involves injecting tiny radioactive spheres into the blood vessels that supply the liver metastases.
View recommendations for IPG786Show all sections
This guideline covers managing Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life.
Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.
Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.
Evidence-based recommendations on axitinib (Inlyta) for previously treated advanced renal cell carcinoma in adults.
This quality standard covers the effective use of antimicrobial medicines (including antibiotics) to reduce the risk of antimicrobial resistance, which is when antimicrobial medicines lose their effectiveness. It covers all settings and all types of antimicrobials for treating bacterial, fungal, viral and parasitic infections. It describes high-quality care in priority areas for improvement.
View quality statements for QS121Show all sections
Sections for QS121
- Quality statements
- Quality statement 1: Advice on self-limiting conditions
- Quality statement 2: Back-up (delayed) prescribing
- Quality statement 3: Recording information
- Quality statement 4: Microbiological samples
- Quality statement 5: Data collection and feedback
- Quality statement 6 (developmental statement): electronic prescribing systems
- Update information
in children and are often non-allergy related, such as colic, reflux, diarrhoea, eczema and faltering growth. Failure to recognise food...